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Quercetin, a Natural Flavonoid 
Interacts with DNA, Arrests Cell 
Cycle and Causes Tumor Regression 
by Activating Mitochondrial 
Pathway of Apoptosis
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Naturally occurring compounds are considered as attractive candidates for cancer treatment and 
prevention. Quercetin and ellagic acid are naturally occurring flavonoids abundantly seen in several 
fruits and vegetables. In the present study, we evaluate and compare antitumor efficacies of quercetin 
and ellagic acid in animal models and cancer cell lines in a comprehensive manner. We found that 
quercetin induced cytotoxicity in leukemic cells in a dose-dependent manner, while ellagic acid showed 
only limited toxicity. Besides leukemic cells, quercetin also induced cytotoxicity in breast cancer 
cells, however, its effect on normal cells was limited or none. Further, quercetin caused S phase arrest 
during cell cycle progression in tested cancer cells. Quercetin induced tumor regression in mice at a 
concentration 3-fold lower than ellagic acid. Importantly, administration of quercetin lead to ~5 fold 
increase in the life span in tumor bearing mice compared to that of untreated controls. Further, we 
found that quercetin interacts with DNA directly, and could be one of the mechanisms for inducing 
apoptosis in both, cancer cell lines and tumor tissues by activating the intrinsic pathway. Thus, our data 
suggests that quercetin can be further explored for its potential to be used in cancer therapeutics and 
combination therapy.
Among different diseases, cancer is still considered as the most detrimental for survival of humans. Chemotherapy 
is considered as the most promising modality for treating cancer. Although chemotherapy against cancer was 
introduced more than five decades ago, its application is still very limited in most of the cancers. Ideally, a chem-
otherapeutic drug should eradicate cancer cells by targeting a particular receptor, protein or DNA specific to 
the neoplastic cells and should reduce tumor burden by inducing cytotoxic and/or cytostatic effects, with least 
collateral damage to adjacent normal cells.
Naturally occurring compounds are considered as the most interesting agents to test for cancer prevention 
and therapy, due to their anticipated multimodal actions and limited toxicity. Phytochemicals may also affect the 
signaling pathways within the cells, including those regulating cell proliferation, activation of apoptosis etc. In 
addition, combined regimens of naturally occurring compounds with standard chemotherapeutic drugs are very 
promising in providing additive or synergistic efficacy. Among various naturally occurring compounds, polyphe-
nols are known to be present in various edible fruits including grapes, berries, walnut, pomegranate, apples, etc. 
Among these, flavonoids consist of a large group of natural, small molecular weight compounds, ubiquitously 
present in almost all fruits and vegetables.
Polyphenols are reported to have anticarcinogenic properties against different cancers. There are several 
studies that address the efficiency of polyphenol containing foods in cancer prevention and therapy. However, 
there are only limited studies to identify individual components responsible for the anticancer properties of 
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polyphenols. Similarly, little is known about mechanism by which such small molecule inhibitors purified from 
plants act on tumor cells.
Quercetin (3,3′ ,4′ ,5,7- pentahydroxy-flavone), is one of the most abundant flavonoids found in fruits and 
vegetables (Suppl. Fig. 1). It has been shown to exert anticancer and antiinflammatory effects1,2. Due to its anti-
proliferative nature and relevance in antihypertensive and neurotropic activity, it has been chemically synthesized 
and commercially sold3–5. There are contradicting reports on its antioxidant as well as oxidative properties6–8, 
which need further evaluation. The ability of quercetin to induce cell cycle arrest also warrants additional inves-
tigation as conflicting findings have been reported. For example, it appears that quercetin treatment could lead 
to cell cycle arrest at G0/G1 in leukemia9,10, or S phase in colorectal carcinoma11 or G2/M phases of the cell cycle 
in breast carcinoma, leukemia and oesophageal adenocarcinoma cell lines12–14. Ellagic acid is also one of the 
phenolic compounds abundantly present in fruits and nuts and is reported to inhibit cell mobility and cell inva-
sion (Suppl. Fig. 1)15. It is known to cause cell cycle arrest at G1 phase and induce apoptosis at a concentration of 
100 μM16.
Quercetin has been used in combination with many naturally occurring compounds like resveratrol1, 
2-methoxyestradiol17, luteolin derivatives18, ellagic acid2, as well as synthetic drugs used in chemotherapy e.g., 
doxorubicin19, cisplatin20 etc. In several cases, combination therapy with quercetin resulted in the synergistic 
effects as well1,17,21.
In spite of various studies suggesting the cytotoxicity of quercetin and ellagic acid in various cancer cell lines, 
the mechanism of action of these flavonoids during tumor regression is largely unclear. Therefore, in the present 
study we investigated anticancer properties of quercetin in a systematic manner, using ex vivo, in vitro and in vivo 
model systems. We found that it induces several fold higher levels of cytotoxicity in cancer cells than ellagic acid. 
Quercetin also induced cytotoxicity in breast cancer cells apart from leukemic cells, however, its effect on normal 
cells was limited or none. Further, we showed that quercetin induces S phase arrest; though, we could not observe 
any detectable ROS production. Quercetin induced tumor regression in mice more effectively than ellagic acid 
and led to ~5 fold increase in survival. Quercetin induced apoptosis both in cancer cell lines and tumor tissues 
by activating intrinsic pathway. Thus our data indicates that quercetin could be developed further as a potential 
anti-cancer agent, both in conventional and combination therapy.
Results
Quercetin induces cytotoxicity in cancer cells. Cytotoxic effect of quercetin and ellagic acid was exam-
ined in three leukemic cell lines (CEM, K562 and Nalm6), two breast cancer cell lines (T47D and EAC) and two 
normal cell lines (293T and MEF1). Cells were treated with increasing concentration of quercetin and ellagic acid 
(10, 50, 100 and 250 μM for 48 h) and cytotoxic effect was assessed by either MTT or trypan blue, and in some 
cases both. Results showed that quercetin induced cytotoxicity in all the leukemic cell lines in a dose-dependent 
manner while ellagic acid exhibited only limited sensitivity (Fig. 1). Among leukemic cells, Nalm6 exhibited max-
imum sensitivity showing reduction in cell viability even at lowest concentration of quercetin (10 μM). IC50 value 
of quercetin was estimated to be 20, 40 and 55 μM at 48 h, in Nalm6, K562 and CEM, respectively. For ellagic acid, 
IC50 was 170, > 250 and 183 μM for Nalm6, K562 and CEM, respectively. Thus, our results showed that quercetin 
induced significantly higher toxicity in all cancer cell lines tested.
Since quercetin exhibited higher toxicity in leukemic cell lines, its effect was evaluated further in the human 
breast cancer cell line, T47D using MTT assay. Results showed a limited sensitivity to quercetin with an IC50 of 
160 μM in T47D cells (Suppl. Fig. 2A). Interestingly, when quercetin was tested against mouse breast cancer cell 
line, EAC, it showed much higher sensitivity (IC50 of 50 μM), while no such effect was observed when ellagic acid 
was used (Suppl. Fig. 2B). However, when normal cell lines (293T and MEF-1) were analyzed using MTT assay, 
quercetin was found to be insensitive (Suppl. Fig. 2A). Evaluation of Nalm6 cells treated with quercetin (20 and 
50 μM) by live dead cell assay following staining with Calcein-A/PI confirmed elevated cytotoxicity induced by 
quercetin in Nalm6 cells (Suppl. Fig. 3).
Hence, our results show that quercetin induced significant toxicity in both leukemic and breast cancer cell 
lines, however, its effect on normal cells was minimal.
Quercetin induces S phase arrest during cell cycle progression followed by apoptosis. Nalm6 
cells were subjected to flow cytometric analyses following treatment with quercetin (20 μM) for 8, 16 and 24 h. 
Results showed a distinct S phase arrest following 16 h of quercetin treatment in Nalm6 cells (Fig. 2A,B). Besides, 
a dose-dependent increase in apoptotic cell population was observed in Sub G1 phase when Nalm6 cells were 
treated with increasing concentrations of quercetin (10, 50, 100, 250 μM for 48 h) as compared to vehicle control 
(Fig. 2C,D). Interestingly, cell cycle arrest at S phase was observed only at lower time point (16 h) while a dose 
dependent increase in Sub G1 population was observed at 48 h (Fig. 2C,D). Thus, results show that quercetin 
induces S phase arrest followed by apoptosis in cancer cells.
Quercetin binds to DNA by intercalation. DNA binding ability of quercetin was tested by incubating 
with calf thymus (CT) DNA, followed by CD spectroscopy. A native B-DNA conformation was observed when 
CT DNA was studied alone, while a negative shift in peak was observed when DNA was incubated with increasing 
concentrations of quercetin (50, 100, 150 μM for 1 h, RT) (Fig. 3A) suggesting an intercalation activity. Ethidium 
bromide stained DNA served as a positive control in which a positive shift was observed at 275 nm and a nega-
tive shift at 248 nm (Fig. 3A). Gel mobility shift assay was performed using supercoiled and linearized (digested 
with EcoRI) form of pUC18 DNA. A shift in the mobility of linearized pUC18 on agarose gel was observed when 
incubated with increasing concentrations of quercetin (10, 50, 100, 150, 200, 250 μM) (Fig. 3B). Besides, when 
covalently closed plasmid DNA was incubated with quercetin, a shift in mobility was observed in the case of 
nicked circle, while an increase in intercalation was observed for supercoiled form in a concentration (10, 50, 100, 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:24049 | DOI: 10.1038/srep24049
150, 200, 250 μM) dependent manner. Ethidium bromide served as positive control for the experiment (Fig. 3C). 
Therefore, our data suggest that quercetin can directly interact with DNA.
Quercetin treatment leads to significant reduction in tumor volume. Breast adenocarcinoma 
developed in Swiss albino mice was used for evaluating antitumor effects of quercetin and ellagic acid. On 12th 
day of injection of Ehrlich Ascites Carcinoma (EAC) cells, when visible tumor was detectable, mice were orally 
administered with 6 doses of either quercetin (1 mg/kg) or ellagic acid (3 mg/kg) on every third day. The respec-
tive doses of compounds were selected based on a pilot study (data not shown). Result showed a remarkable 
reduction in tumor volume when treated with each of the compounds as compared to untreated control animals 
bearing tumor after 10th day of treatment (Fig. 4). However, the reduction in tumor size was more significant in 
case of quercetin treated animals, since the effect is pronounced at a dose, which is three fold lower than that of 
ellagic acid (Fig. 4).
Administration of quercetin improves the lifespan of tumor bearing mice, with no side 
effects. Increase in life span was evaluated in case of quercetin treated (1 mg/kg) tumor bearing mice as 
described in Materials and Methods. While untreated control mice survived for a maximum of only ~50 days, 
treatment with quercetin led to a ~5 fold increase in the life span for atleast 40% of mice (Fig. 5A). This confirms 
that administration of quercetin did not result in any side effects. Thus, our data shows that quercetin treatment 
in mice leads to lower tumor load, increased survival and minimal side effects.
Histopathological studies were done on tumor section of control and quercetin treated mice at 30th and 
45th days of treatment, by hematoxylin and eosin staining (Fig. 5B). High nuclear staining by hematoxylin was 
observed in control tumor animals (Fig. 5B; a–c) thus showing the presence of large number of proliferating 
cells as compared to treated tumor (Fig. 5B; d–f). While control tumor muscle at 30th day of tumor development 
showed distorted histology and infiltration of tumor cells (Fig. 5B; a–c), following quercetin treatment, cell pro-
liferation and damage in muscle architecture was limited (Fig. 5B; d–f). This was further reduced on 45th day of 
quercetin treatment (Fig. 5B; j–l) in comparison to control (Fig. 5B; g–i).
TUNEL staining was observed in quercetin treated tumor tissue section (30th day) in comparison to untreated 
control tumor tissues (Fig. 6A,B) suggesting the presence of DNA fragmentation, which is a characteristic feature 
of apoptosis. Thus, our data suggest that quercetin treatment might activate apoptosis in tumor tissues.
Figure 1. Determination of the cytotoxic effect of quercetin and ellagic acid on leukemic cell lines. Cell 
viability and cell proliferation was determined by MTT and trypan blue assays respectively, on CEM, K562 and 
Nalm6 cell lines. Cell lines were treated with quercetin (QR) (A) or ellagic acid (EA) (B) for 48 h. DMSO treated 
cells served as vehicle control (denoted as ‘C’) in both the cases. Concentrations of compound used were 10, 50, 
100 and 250 μM. ‘ns’ is ‘not significant’ while ‘*’ represents significance (*P < 0.05, **P < 0.01, ***P < 0.001). 
Data represents SEM of three independent repeats.
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Immunohistochemical analysis showed strong nuclear staining of Ki-67 (Fig. 6C; b), a cellular proliferation 
marker, in untreated tumor tissue sections (30th day). In contrast, substantially less number of Ki67 positive 
cells were observed in quercetin treated tissue sections (Fig. 6Cc,D). Further, we observed significant increase 
in p53 and p-p53 (phospho-p53) positive cells in quercetin treated tumor sections (Fig. 6Cf,i,D), as compared 
to untreated controls (30th day) (Fig. 6Ce,h) suggesting activation of apoptotic pathway. Tissue sections with no 
primary antibody served as negative control in each case (Fig. 6Ca,d,g).
Quercetin treatment results in depolarization of mitochondrial membrane potential. 
Depolarization in mitochondrial membrane potential was studied by staining treated and untreated cells with JC1 
dye. The depolarization leads to a shift from red to green fluorescence leading to the release of CYTOCHROME 
C. Interestingly, a significant shift from red to green fluorescence was observed when Nalm6 cells were treated 
with increasing concentrations of quercetin (10, 20, 50, 100 μM) for 12 h as compared to vehicle control. 2,4 
dinitro phenol (2,4-DNP) was used as a positive control (Fig. 7A). Hence our data suggest the involvement of 
mitochondrial pathway of apoptosis during quercetin mediated cytotoxicity.
Accumulation of ROS after treatment with antitumor compounds is one of the factors responsible for cells 
undergoing DNA damage and apoptosis. We were interested in checking whether Nalm6 cells were undergoing 
cell death due to ROS production. In order to test this, the cells were treated with quercetin (25 μM) for different 
time points and subjected to flow cytometry. H2O2 induced ROS production served as a positive control. Results 
showed that quercetin did not induce any significant change in the levels of ROS (Suppl. Fig. 4A,B) suggesting 
that cell death induced by quercetin was not due to ROS production.
Quercetin treatment leads to apoptosis. In order to confirm whether the cytotoxicity induced by 
quercetin is indeed due to apoptosis, rather than necrosis, annexin V-FITC/PI staining was performed following 
Figure 2. Effect of quercetin on cell cycle progression in Nalm6 cells. (A) Nalm6 cells (0.75 × 105 cells/ml) 
were incubated at 37 °C with quercetin (20 μM) for 8, 16 and 24 h. Following incubation, cells were harvested, 
fixed and stained with propidium iodide and analysed by flow cytometry. (B) Bar diagram showing the 
percentage of cells in S phase of cell cycle. (C) Cell cycle distribution of Nalm6 cells after treating with increasing 
concentrations (10, 50, 100, 250 μM) of quercetin for 48 h. Histogram resulted after flow cytometry analysis is 
shown. (D) Bar diagrams showing percentage of cells in each phase of cell cycle. C represents cells alone, while 
VC stands for DMSO treated vehicle control. In each case M1 represents G1 phase, M2 represents G2 phase, M3 
represents S phase and M4 represents Sub G1 phase. Error bars represents SEM of two independent repeats and 
‘*’indicates the significance, *P < 0.05.
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quercetin treatment. Nalm6 cells treated with quercetin (0, 20, 50 μM for 6, 12, 18, 24 and 48 h) were subjected 
to annexin V-FITC/PI double-staining followed by flow cytometry (Fig. 7B). Apoptotic cells can be detected by 
virtue of binding of annexin V-FITC to phosphotidyl serine (PS) present on the outer side of the cell membrane. 
In normal cells PS is predominantly present on cytosolic side of the membrane, while it gets translocated towards 
outer side of the membrane when cells undergo apoptosis. Results showed a concentration dependent increase in 
early apoptotic cells upon treatment with quercetin for 6 and 12 h, while an increase in late apoptotic cells were 
observed at 18, 24 and 48 h of treatment suggesting activation of apoptotic pathways (Fig. 7B). Further, confocal 
microscopic analysis showed cells stained with annexin V-FITC (green fluorescence), following treatment with 
quercetin (20 μM) suggesting cells in early apoptotic phase (Suppl. Fig. 5). In contrast, most of the cells were 
stained with annexin V-FITC/PI (green and red) at higher concentrations of quercetin (50 μM) indicating that 
these cells were undergoing late apoptosis (Suppl. Fig. 5).
Quercetin activates intrinsic pathway of apoptosis. In order to find out the mechanism by which 
quercetin induces apoptosis, western blotting studies were performed to evaluate the alterations in the pro-
tein expression. Nalm6 cells were treated with increasing concentrations of quercetin (0, 10, 20 μM for 24 h), 
lysate was prepared and analyzed for various apoptotic pathway proteins. Results showed an increase in level 
of p53 and p-p53 along with cleavage of MCL1, an apoptotic marker (Fig. 8A; Suppl. Fig. 6). A reduction in 
level of anti-apoptotic proteins BCL2 and BCL-xL was observed while a concomitant increase in level of BAX, 
a proapoptotic protein was also noted (Fig. 8A). Further, the release of CYTOCHROME C in conjunction with 
SMAC/DIABLO indicated the activation of mitochondrial intrinsic pathway resulting in apoptosis (Fig. 8A). 
The observed increase in the level of activated CASPASE 3, cleaved CASPASE 9 and PARP1 further confirmed 
such a conclusion (Fig. 8A). The data was quantitated, normalized with respect to tubulin and represented as bar 
diagram with standard error bar (Suppl. Fig. 6).
DNA fragmentation is one of the hallmarks of apoptosis differentiating between the necrotic and apoptotic 
modes of cell death. To test for the presence of DNA fragmentation, Nalm6 cells were treated with different 
Figure 3. Determination of mode of action of quercetin. (A) Conformational changes induced by quercetin 
in DNA was assessed by incubating calf thymus (CT) DNA with different concentrations of quercetin (50, 100, 
150 μM) for 1 h at room temperature. Following incubation, CD spectra was recorded at wavelength of  
210–320 nm. Ethidium bromide (10, 20 μM) stained DNA served as a positive control. ‘0 μM’ is the untreated 
CT DNA. Boxed region represents the shift in DNA peak due to intercalation of the compounds. (B,C) Gel 
mobility shift assay was performed using 100 ng pUC18 DNA. The linearized (digested with EcoRI) (B) and 
supercoiled (C) pUC18 DNA were incubated at room temperature for 1 h with increasing concentrations 
of quercetin (10, 50, 100, 150, 200, 250 μM) and products were resolved. Ethidium bromide (2.5, 10, 25 μM) 
stained DNA served as positive control for the assay. Stained DNA was resolved on 1.2% agarose gel at 30 V. 
Boxes indicate the shift in the DNA band position due to intercalation.
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concentrations of quercetin (0, 10, 50, 100, 250 μM) for 48 h. An increase in endonuclease mediated cleaved 
DNA ladder intensity was observed with increasing concentration of quercetin after 48 h further confirming the 
apoptosis (Fig. 8B). 5-fluorouracil (5-FU), a compound known for inducing DNA fragmentation was used as the 
positive control for the assay.
Discussion
Development of safe, novel and effective drugs with less toxicity and lesser side effects is needed for cancer thera-
peutics. DNA double strand breaks, if not repaired can also lead to genomic instability and cancer. Hence target-
ing DSB repair genes is one of the methods for cancer therapeutics22. Previous studies from our lab have shown 
cytotoxic properties of extracts prepared from fruits such as strawberry23 and sapota24, Methyl Angolensate puri-
fied from callus of Red wood tree25–27 and many synthetic compounds like MPTQ28,29, SCR722,30,31, Levamisole 
derivative (4a)32, ASHD33, hydantoin derivatives DFH and DCH34 etc. on various cancer cells. These compounds 
have been shown to be antiproliferative and interfered with different cellular signaling pathways to induce 
apoptosis.
Phytochemicals are extensively used for evaluation of their cancer therapeutic properties35. Quercetin and 
ellagic acid are two such compounds studied for their anticancerous and antiproliferative properties as single 
molecule or in combination1,2,21,36. These natural flavonoids are thought to act as antioxidants and provide defense 
against several pathologies.
Figure 4. Evaluation of effect of quercetin and ellagic acid on tumor growth in mice. Solid tumor was 
induced in female Swiss albino mice by injecting EAC cells intramuscularly. (A) Six doses of quercetin (1 mg/kg  
body wt) and (B) ellagic acid (3 mg/kg body wt) were administered every third day from 12th day of EAC 
cell injection. Data shows the tumor volume at different time intervals with and without treatment of the 
compound. Data was collected from three independent experiments with a set of five animals each. Error bars 
indicate the standard deviation (SD) of three independent experiments. P value was calculated by comparing 
the mean of untreated control group (EAC alone) and with mean of quercetin treated group, *P < 0.05, 
***P < 0.001.
www.nature.com/scientificreports/
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Previous reports showed that both quercetin and ellagic acid induced cytotoxicity in various human cancer 
cell lines, with varying sensitivity1,12,16,37. In our ex vivo assays, we find that quercetin induces cytotoxicity in leu-
kemic cells effectively; pre-B cell line, Nalm6 being most sensitive with an IC50 value of 20 μM (Fig. 1). A varying 
range of IC50 for quercetin was reported earlier38–43, which ranges from 10 μM to > 100 μM. In our studies, querce-
tin was more cytotoxic compared to ellagic acid. Between the breast cancer cell lines tested, the one derived from 
mouse showed more sensitivity. However, normal cells derived from human embryonic kidney as well as mouse 
embryonic fibroblasts were insensitive to quercetin. The ability of quercetin to spare normal cells has also been 
reported previously44. Chronic myelogenous leukemia cell line, K562 was reported to display resistance to most 
of the anticancerous drugs. However, we observe that it was sensitive towards quercetin, which was consistent 
with a previous study8.
A prominent cell cycle arrest at S phase was noted upon treatment with quercetin in Nalm6 cells at early time 
points (16 h). Besides, an increase in cells in Sub G1 phase was observed in a dose dependent manner, when 
Nalm6 cells were treated for 48 h. This suggests that quercetin might induce DNA damage, which need to be cor-
rected before cell division takes place. Considering the ability of quercetin to interact with DNA, the observation 
can be easily explained (see below). A similar S phase arrest has been observed previously as well5,11. However, as 
reported by others, we did not observe either G0/G1 or G2/M arrest9,10,12–14. Difference in the cancer type used 
may account for such a disparity in the observation.
Consistent with the cytotoxic effect induced by quercetin, we find that even in the tumor tissues, it induced 
3-fold more cytotoxicity than ellagic acid. While an impressive, 1 mg/kg quercetin was sufficient for significant 
inhibition of tumor growth in breast adenocarcinoma bearing mice, for an equivalent effect we had to administer 
3 mg/kg of ellagic acid. The dose at which tumor regression was observed in the current work was 10 times lower 
than that used in past studies19,45. This discrepancy could be due to differences in the cancer cell types or mouse 
strains used for developing tumor. EAC cells used in the present study are undifferentiated malignant cell lines 
derived from mice breast adenocarcinoma, commonly used for inducing tumors in mice and used to assess the 
anticancer effect of various compounds24,28,31,46–48. Thus we conclude that quercetin is more effective than ellagic 
acid in inducing cytotoxicity in different cancer cells.
A 5-fold increase in life span was observed in tumor bearing animals following treatment with quercetin com-
pared to that of untreated tumor bearing mice. This indicates that quercetin induced cytotoxicity in tumor cells 
without significantly affecting the normal cells. Remarkably, at least 40% of the tumor bearing animals survived 
upto 250 days. Histological studies and Ki-67 staining confirmed a reduction in proliferative cells and a low dam-
age in muscle architecture in quercetin treated tumor animals in comparison to the untreated control.
Intercalation of small molecules causes conformational changes in DNA, which can affect physiological pro-
cesses such as replication, transcription, translation and repair. CD spectroscopic and gel shift studies showed that 
quercetin could intercalate to DNA (Fig. 3), which was also consistent with a recent report38. DNA intercalation 
is one of the mechanisms by which anticancerous drugs cause DNA damage, accumulation of which could cul-
minate in apoptosis. The observed cell cycle arrest at S phase was also consistent with the plausible induction of 
Figure 5. Evaluation of effect of quercetin on survival of tumor bearing mice and its side effects.  
(A) Kaplan-Meier survival curve of female Swiss albino mice treated with quercetin (1 mg/kg, six doses). 
The experiment was performed in two independent batches with a set of five animals each. ‘**’ represents 
significance, **P < 0.01. (B) Histopathologic analysis of tumor following quercetin treatment. Histological 
sections of thigh of tumor bearing mouse with (treated tumor) and without treatment (control tumor) of 
quercetin after 30th day (d–f) and (a–c) and 45th day (j–l) and (g–i) of tumor development. Final magnifications 
shown are 100× (a, d, g and j panel), 200× (b, e, h and k panel), and 400× (c, f, i and l panel). ‘M’ is muscle, ‘TC’ 
is tumor cells and ‘ITC’ stands for infiltering tumor cells.
www.nature.com/scientificreports/
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DNA damage following DNA intercalation within the cells. However, we could not observe any ROS generation 
suggesting that it might act as an antioxidant, which was also consistent with another study49.
Depolarization in mitochondrial membrane potential in Nalm6 cells, TUNEL staining positive cells in tumor 
tissues, Annexin V/PI staining showing early and late apoptotic cells and DNA fragmentation as detected by gel 
assays suggest activation of apoptosis following exposure to quercetin (Fig. 8C). Apoptosis involve downregula-
tion of antiapoptotic proteins and upregulation of proapoptotic proteins50. Treatment with quercetin resulted in 
the upregulation of p53, which was consistent with an earlier report51. Downregulation of antiapoptotic protein 
BCL2 and BCL-xL, upregulation of BAX, p-p53, release of CYTOCHROME C, SMAC/DIABLO as well as cleav-
age of CASPASE 3, CASPASE 9, PARP1 and MCL1 suggested the involvement of intrinsic mitochondrial pathway 
(Fig. 8C).
Quercetin is suggested to affect multiple cell signaling processes in cancers and various other diseases 
(Fig. 8C). Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) was identified as a target of quercetin in 
prostate cancer cell line, PC352. Besides, quercetin shown to inhibit hedgehog signaling pathway in prostate can-
cer53. Previous studies also showed that quercetin can enhance TRAIL mediated apoptosis in colon adenocarci-
noma cells54. Another study suggested set of kinases including ABL1, Aurora-A, B, C as its target55. Therefore, 
it is possible that quercetin treatment might affect multiple targets within the cells, including DNA by direct 
intercalation as shown in the present study.
In conclusion, quercetin can induce cytotoxicity through multiple routes of action. Our results show that 
quercetin, a DNA intercalator induces cytotoxicity in cancer cell lines and tumor tissues in mice by activating 
intrinsic pathway of apoptosis. Therefore, our results suggest that quercetin is a promising candidate in cancer 
therapeutics.
Figure 6. Evaluation of quercetin mediated cytotoxicity and its mechanism in tumor tissues. (A) TUNEL 
assay showing DNA fragmentation on 30th day of quercetin treated tumor tissues in comparison to untreated 
control tumor. Brown color nuclei indicate DAB staining showing DNA breaks, while nuclei with intact DNA 
were stained with methyl green. Final magnifications shown are 200× and 400× . (B) Bar diagram with SEM 
(n = 5) represents % TUNEL positive nuclei in tumor control and quercetin treated mice tissues. ‘*’ represents 
P < 0.05. (C) Immuno staining was performed on paraffin embedded tissue sections for Ki-67, p-p53 and 
p53 using respective antibodies in control tumor tissues and quercetin treated tumor tissues after 30th day of 
treatment. Final magnification shown is 400×. (D) The images of IHC were quantified and plotted as SEM 
(n = 5). ‘*’represents significance (*P < 0.05, **P < 0.01).
www.nature.com/scientificreports/
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Materials and Methods
Cell lines and cell culture. Human chronic mylegenous leukemia cell line (K562), human acute lympho-
blastic leukemia cell line (CEM); human embryonic kidney epithelial cell line (HEK 293T), human breast cancer 
cell lines (T47D), mouse breast cancer cell lines (EAC) and mouse embryonic fibroblast cell line (MEF-1) were 
purchased from National Centre for Cell Science, Pune, India. Human B cell leukemia cell line (Nalm6) was a 
gift from M. Lieber (USA). K562, CEM, T47D and Nalm6 were cultured in RPMI1640 (Sera Lab, USA) with 10% 
FBS (GIBCO, BRL), 100 U of Penicillin G/ml and 100 μg of streptomycin/ml at 37 °C in humidified atmosphere 
containing 5% CO2. 293T, EAC and MEF were cultured in DMEM containing 10% FBS (GIBCO, BRL), 100 U of 
Penicillin G/ml and 100 μg of streptomycin/ml.
Trypan blue exclusion assay. Effect of quercetin and ellagic acid on cell viability was determined on CEM, 
K562 and Nalm6 cell lines by trypan blue exclusion assay as described29,34. Cells were seeded at a density of 
0.75 × 105 cells/ml for 24 h and treated with different concentrations of quercetin and ellagic acid (0, 10, 50, 100 
Figure 7. Assessment of effect of quercetin on mitochondrial transmembrane potential (ΔψM) and 
apoptosis. (A) Nalm6 cells were treated with quercetin (10, 20, 50 and 100 μM) for 12 h. Cells were harvested, 
stained with JC1 dye for 20 min at 37o C and analyzed using flow cytometer. Depolarization in mitochondrial 
membrane potential was assessed by a shift from red to green fluorescence, where red indicates JC1 aggregates 
in intact mitochondria and green represents green fluorescing monomers in cytosol depicting loss in 
mitochondrial potential. VC represents DMSO treated vehicle control. Bar diagram shows percentage of 
depolarized population after quercetin treatment. ‘*’represents significance where *P < 0.05, **P < 0.01. 2,4 
DNP treated cells served as positive control. (B) Annexin V/PI dual staining of Nalm6 cells for the detection 
of apoptotic stages following treatment with quercetin. Nalm6 cells were stained with annexin V-FITC/PI after 
treatment with quercetin (0, 20 and 50 μM) for 6, 12, 18, 24 and 48 h. Cells were analysed quantitatively as well 
as qualitatively. Histogram showing distribution of annexin V-FITC/PI stained cells. In each panel lower left 
quadrant shows the cells negative to both annexin V-FITC and PI staining, lower right panel shows the cells 
stained with annexin V (early apoptotic cells), upper left quadrant shows cells stained with PI alone (necrotic 
cells) and upper right shows the cells positive for both annexin V and PI (late apoptotic cells). Histogram 
showing distribution of early and late apoptotic cells as well as necrotic cells following treatment with 
quercetin for 6, 12, 18, 24 and 48 h, respectively. Error bar represents standard error mean (SEM) of atleast two 
independent repeats. P value has been calculated as compared to DMSO control in each case where *P < 0.05, 
**P < 0.01, ***P < 0.001.
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and 250 μM) for 48 h. IC50 value was determined by counting the cells after trypan blue staining using DMSO 
treated cells as vehicle control. The experiment was repeated a minimum of three independent times and data was 
presented as bar diagram with standard error mean (SEM).
MTT assay. Effect of quercetin and ellagic acid on cell proliferation was assessed by MTT assay as described 
earlier31,56. Leukemia cell lines (CEM, K562, Nalm6), breast cancer cell lines (EAC and T47D) or normal cell lines 
(293 T and MEF-1) were seeded (0.75 × 105 cells/ml) for 24 h at 37 °C and then treated with 0, 10, 50, 100 and 
250 μM of quercetin or ellagic acid for 48 h and subjected to MTT assay. Experiment was repeated a minimum of 
three times independently, each with duplicate sets of reaction and presented as bar diagram along with standard 
error mean (SEM).
Cell cycle analysis by flow cytometry. Cell cycle analyses was performed in Nalm6 cell line as 
described29,33. A time course experiment was conducted on Nalm6 cells following treatment with quercetin 
(20 μM) for 8, 16 and 24 h. Besides Nalm6 cells were also treated with increasing concentrations of quercetin 
(0, 10, 50, 100, 250 μM) for 48 h. In both the experiments cells were seeded at 0.75 × 105 cells/ml, cells were 
harvested after quercetin treatment, washed, fixed and incubated with RNase A. Cells were then stained with 
propidium iodide (50 μg/ml) and readings were acquired in flow cytometer (BD Biosciences FACS Calibur, USA). 
Figure 8. Effect of quercetin on expression of apoptotic proteins and mechanism of action. (A) Expression 
level of apoptotic proteins following treatment with quercetin. Cell lysate was prepared after treating Nalm6 
cells with quercetin (0, 10, 20 μM, for 24 h). Protein lysate was resolved on SDS-PAGE and immunoblotting 
was performed using appropriate primary and secondary antibodies. Expression pattern was studied for p53, 
p-p53, BCL2, BCL-xL, BAX, MCL 1, CYTOCHROME C, SMAC/DIABLO, activated CASPASE 3, CASPASE 
9, PARP1 and Tubulin. Ponceau stained PVDF membrane after protein transfer acted as a control for equal 
protein loading. (B) Detection of DNA fragmentation in Nalm6 cells following treatment with quercetin. 
Chromosomal DNA was extracted after treatment with quercetin (10, 50, 100, 250 μM). The purified DNA was 
resolved on 2% agarose gel at 50 V for 5 h. M is hyper ladder I (Bioline). 5-fluorouracil (5-FU; 100 μM) was used 
as positive control. (C) Proposed model for quercetin induced apoptosis leading to cytotoxicity. Treatment 
of cancer cells with quercetin leads to apoptosis through activation of mitochondrial intrinsic pathway. Since 
quercetin is a DNA intercalator, it might induce DNA damage, which leads to the upregulation of p53. This 
results in the down regulation of antiapoptotic protein, BCL2 and cleavage of MCL1. CYTOCHROME C and 
SMAC/DIABLO are released due to loss in mitochondrial membrane potential. SMAC/DIABLO inhibits IAPs 
(inhibitors of apoptosis proteins), while CYTOCHROME C release leads to cleavage of CASPASE 9, which in 
turn cleaves CASPASE 3. CASPASE 3 leads to fragmentation and degradation of cellular DNA and activation of 
PARP1 resulting in apoptosis.
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A minimum of 10,000 cells were acquired per sample and data was analyzed by using WinMDI 2.9 software. 
Experiments were repeated a minimum of two independent times and data is presented along with error bars.
Circular Dichroism (CD). DNA binding ability of quercetin was studied using CD as described earlier31. 
Quercetin (0, 50, 100, 150 μM) was incubated with sheared calf thymus (CT) DNA in buffer (10 mM Tris HCl, 
15 mM NaCl) for 1 h and spectra were recorded at a wavelength of 210–320 nm on JASCO J-810 spectropolar-
imeter. Spectra for buffer alone and buffer with corresponding concentrations of quercetin without DNA were 
subtracted from the experimental data. CD spectra of ethidium bromide (0, 10, 20 μM) incubated with CT DNA 
served as a positive control.
DNA mobility shift assay. The assay was performed as described earlier31. 100 ng of supercoiled and line-
arized pUC18 plasmid was incubated with quercetin (0, 10, 50, 100, 150, 200, 250 μM) at room temperature for 
1 h and resolved on agarose gel. For further details refer supplementary methods.
Animal and ethics statement. Mice were maintained in strict accordance with the principles and guide-
lines of the ethical committee for animal care of Indian Institute of Science (IISc) in accordance with Indian 
National Law on animal care and use. The experiments designed for the present study were approved by 
Institutional Animal Ethical Committee (Ref. CAF/Ethics/289/2012) IISc, Bangalore, India. For other details 
refer supplementary methods.
Preparation of EAC cells and tumor induction. Fixed number of ehrlich ascites carcinoma cells (1 × 106 
cells/animal) were injected in the peritoneal cavity of donor mouse and allowed to multiply. The cells were with-
drawn, diluted in 1X PBS, counted and re-injected to the right thigh of the experimental animals (1 × 106 cells/
animal) for developing solid tumor.
Evaluation of anticancer effects of quercetin and ellagic acid on tumor development. Total of 
15 mice were taken in a batch, of which 10 were injected with EAC cells in their right thigh to develop solid tumor. 
5 mice served as no tumor control, which did not receive quercetin or ellagic acid treatment (Group I). 10 mice 
with tumor were divided into two groups based on size of the tumor so that mean tumor size of each group remain 
equal, one of which served as tumor control and received no treatment (Group II), while quercetin (1 mg/kg) 
or ellagic acid (3 mg/kg) was administered to the other by oral gavage method on 12th day of EAC injection 
when small tumor was visible (Group III). This group received 6 doses of compound every 3 days. The study was 
repeated for three independent batches. The dose selected for final study was based on a pilot study conducted 
using different doses of quercetin and ellagic acid (1, 3 and 10 mg/kg).
Tumor volume was determined by measuring tumor diameter after every 4 days for each animal using ver-
nier calipers as described24,28,31. Tumor volume was calculated by using the formula, V = 0.5ab2 where ‘a’ and ‘b’ 
represents major and minor diameter, respectively31. After 30th and 45th days one animal was sacrificed from 
each group by cervical dislocation and tissues were fixed separately for normal, control and treated animals from 
multiple batches.
Determination of effect of quercetin on survival of tumor animals. The % survival of quercetin 
treated mice was calculated and compared with control animals. Five animals bearing tumor were taken in each 
control and quercetin treated groups. The study was done in two independent batches. The death pattern of 
control and treated animals was reported and percentage increase in life span was calculated using the formula 
[(T-C)/C] × 100, where T indicates the time of survival of treated animals while C represents survival time of 
control animals24,28,46. The treated animals were monitored for at least 250 days.
Histological evaluation. Tumor tissues from control and quercetin treated animals were collected. Tissues 
were embedded in paraffin wax and sections of 5 μm were cut in rotary microtome (Leica Biosystems, Germany). 
Sections were de-paraffinized and hematoxylin and eosin staining was done as described23,57. Sections were eval-
uated for structural changes using light microscope (Carl Zeiss, Germany) and images were captured.
TUNEL assay. Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay was 
performed using DNA fragmentation Detection Kit (Calbiochem, USA). For further details refer supplementary 
methods.
Immunohistochemistry (IHC). Immunohistochemical staining was performed on quercetin treated tissues 
sections as described before31,57. For further details refer supplementary methods.
JC1 staining to detect change in mitochondrial membrane potential. 5,5’,6,6’-tetrachloro-1,1’,3,3’ 
tetraethylbenzimidazolylcarbocyanine iodide/chloride (JC-1), a fluorescent carbocyanin dye, was used to check 
the transmembrane potential (Δψ M) of mitochondria25. For further details refer supplementary methods.
Annexin V-FITC/propidium iodide (PI) staining for apoptotic stages. Annexin V-FITC/PI staining 
was carried out to detect early and late apoptotic cellular stages, as described34. For further details refer supple-
mentary methods.
Immunoblotting. Nalm6 cell lines were seeded at a density of 0.75 × 105 cells/ml for 24 h. Following treat-
ment with quercetin (0, 10, 20 μM, for 24 h), cells were harvested, and lysate was prepared in RIPA buffer (25 mM 
Tris (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) as described34,57. Protein con-
centration was determined by Bradford assay. Approximately, 30 μg lysate was resolved on 10–12% SDS-PAGE 
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and transferred onto the PVDF membrane (Millipore, USA). Membrane was blocked and incubated with respec-
tive primary antibodies (BCL2, BAX, MCL1, CASPASE 9, activated CASPASE 3, CYTOCHROME C, p53, p-p53, 
SMAC/DIABLO, BCL-xL, PARP1, Tubulin) at 4 °C overnight. Blots were washed, incubated with HRP-conjugated 
secondary antibodies, developed using chemiluminescent solution (ImmobilonTM western, Millipore, USA) and 
scanned by using gel documentation system (ImageQuant LAS4000, GE, USA). The experiment was repeated a 
minimum of three independent times.
DNA fragmentation assay. Nalm6 cells were treated with quercetin (0, 10, 50, 100, 250 μM) as described 
above and DNA fragmentation analysis was performed58. For further details refer supplementary methods.
Statistical analysis. Data was expressed as mean ± SEM for normal and experimental animals. Statistical 
analysis was performed by two way ANOVA and student’s t-test using software Graph pad prism 5.1. Values were 
considered significant when P ≤ 0.05. Kaplien-Meier survival curve was also plotted using Graph pad prism 5.1.
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